Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
To the Editor: I would like to add a cautionary
comment to Dr Topol’s Editorial discussing the apparent prothrombotic
hazard of COX-2 inhibitors.1 The excess number
of thrombotic events with rofecoxib and celecoxib in the trials assessing
their ability to inhibit the development of colonic adenomas is potentially
a confounding effect generated by their analgesic properties.
Pollack S. Arthritis Medications and Cardiovascular Events. JAMA. 2005;293(16):1975-1977. doi:10.1001/jama.293.16.1976-b